Skip to content
10-Q

Quarterly Report

IGM Biosciences, Inc.

0000950170-25-070300

← back to feed
Filed
May 13, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted Q1 2025 · Mar 31, 2025 61.16M sh
Shares Diluted Q1 2025 · Mar 31, 2024 60.11M sh
Capex Q1 2025 · Mar 31, 2025 $31K
Capex Q1 2025 · Mar 31, 2024 $2.48M
Operating Cash Flow Q1 2025 · Mar 31, 2025 −$32.52M
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$42.42M
Cash And Equivalents Q1 2025 · Mar 31, 2025 $36.88M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $26.5M
Cash And Equivalents Q1 2025 · Mar 31, 2024 $79.17M
Stockholders Equity Q1 2025 · Mar 31, 2025 $698K
Stockholders Equity Q1 2025 · Dec 31, 2024 $48.17M
Stockholders Equity Q1 2025 · Mar 31, 2024 $161.25M
Stockholders Equity Q1 2025 · Dec 31, 2023 $203.23M
Current Liabilities Q1 2025 · Mar 31, 2025 $28.2M
Current Liabilities Q1 2025 · Dec 31, 2024 $37.64M
Total Liabilities Q1 2025 · Mar 31, 2025 $206.19M
Total Liabilities Q1 2025 · Dec 31, 2024 $217.54M
Current Assets Q1 2025 · Mar 31, 2025 $161.04M
Current Assets Q1 2025 · Dec 31, 2024 $193.62M
Total Assets Q1 2025 · Mar 31, 2025 $206.89M
Total Assets Q1 2025 · Dec 31, 2024 $265.71M
Eps Diluted Q1 2025 · Mar 31, 2025 −$0.86
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.83
Eps Basic Q1 2025 · Mar 31, 2025 −$0.86
Eps Basic Q1 2025 · Mar 31, 2024 −$0.83
Sga Expense Q1 2025 · Mar 31, 2025 $11.05M
Sga Expense Q1 2025 · Mar 31, 2024 $10.54M
Rd Expense Q1 2025 · Mar 31, 2025 $22.34M
Rd Expense Q1 2025 · Mar 31, 2024 $43.82M
Net Income Q1 2025 · Mar 31, 2025 −$52.89M
Net Income Q1 2025 · Mar 31, 2024 −$49.82M
Operating Income Q1 2025 · Mar 31, 2025 −$54.78M
Operating Income Q1 2025 · Mar 31, 2024 −$53.86M